New York, NY -- (SBWIRE) -- 12/06/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Softbank Corp (Japan(OTCMKTS:SFTBY), Berkshire Hathaway Inc (NYSE:BRK.B), Keryx Biopharmaceuticals (NASDAQ:KERX), U.S. Bancorp (NYSE:USB)
Softbank Corp (Japan(OTCMKTS:SFTBY) showed a volume of 342,714.00 shares by the end of last trade whereas the average volume of the stock remained 247,742.00 shares. The stock opened the session at $42.00 but then moved to $42.68. At that price, the stock showed a positive performance of 2.35%.
Will SFTBY Continue To Move Higher? Find Out Here
Berkshire Hathaway Inc (NYSE:BRK.B) opened the session at $115.01 and closed the session at $11496. The stock showed a negative performance of -0.29% in previous trading session. Berkshire Hathaway Inc. (Berkshire) is a holding company owning subsidiaries engaged in a number of diverse business activities. The Company is engaged in the insurance businesses conducted on both a primary basis and a reinsurance basis, a freight rail transportation business and a group of utility, and energy generation and distribution businesses. Berkshire also owns and operates a number of other businesses engaged in a variety of activities.
Has BRK.B Found The Bottom And Ready To Gain Momentum? Find Out Here
Keryx Biopharmaceuticals (NASDAQ:KERX) opened the session at $14.56 and closed the session at $12.94. The stock showed a negative performance of -11.85% in previous trading session. The beta of the stock remained 3.93. Keryx Biopharmaceuticals, Inc. (Keryx) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease. The Company is developing KRX-0401, an oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, and also affects a number of other key signal transduction pathways, including the Jun N-terminal kinases pathway, all of which are pathways associated with programmed cell death,
Why Should Investors Buy KERX After the Recent Fall? Just Go Here and Find Out
U.S. Bancorp (NYSE:USB) the stock decreased/ -1.00% and finished the session at $38.61. The beta of the stock remained 1.16. U.S. Bancorp (U.S. Bancorp) is a multi-state financial services holding company. It provides a range of financial services, including lending and depository services, cash management, foreign exchange and trust and investment management services. It also engages in credit card services, merchant and automated teller machine (ATM) processing, mortgage banking, insurance, brokerage and leasing. The Company operates in five segments: Wholesale Banking and Commercial Real Estate, Consumer and Small Business Banking,
Will USB Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)